INS and breast cancer: Certain types of sulfonylureas, thiazolidinediones, and insulin analogs have been shown to increase cancer risk, among which the long-acting insulin analog insulin Glargine could increase the risk of breast cancer,[54,55] whereas metformin therapy significantly reduced the overall incidence and mortality rates of cancer by 14% and 30%, respectively,[56,57] including EC and ovarian cancer.